ONXX Insider Trading Activity and SEC Form 4 Filings
ONXX insider trading summary
No open-market insider purchases or sales of Onyx Pharmaceuticals Inc (ONXX) have been reported on SEC Form 4 in the past 12 months.
Latest ONXX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Aug 12, 2013 | Helen Torley | EVP, Chief Commercial Officer | Sell | $135K (1,061 @ $126.92) |
| Aug 12, 2013 | Helen Torley | EVP, Chief Commercial Officer | Sell | $1.0M (8,250 @ $126.89) |
| Aug 8, 2013 | Matthew K Fust | EVP & Chief Financial Officer | Sell | $319K (2,492 @ $128.21) |
| Aug 7, 2013 | Suzanne M Shema | EVP, GC and Corp. Secretary | Sell | $534K (4,052 @ $131.86) |
| Aug 6, 2013 | Kaye I Foster-Cheek | SVP, Global Human Resources | Sell | $67K (500 @ $133.68) |
| Aug 6, 2013 | Kaye I Foster-Cheek | SVP, Global Human Resources | Sell | $1.1M (8,378 @ $132.76) |
| Jul 30, 2013 | Lopez Antonio J Grillo | Director | Sell | $197K (1,500 @ $131.26) |
| Jul 30, 2013 | Corinne H Nevinny | Director | Sell | $197K (1,500 @ $131.26) |
| Jul 26, 2013 | Matthew K Fust | EVP & Chief Financial Officer | Sell | $789K (6,043 @ $130.50) |
| Jul 26, 2013 | Lopez Antonio J Grillo | Director | Sell | $261K (2,000 @ $130.50) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.